Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Monthly Macro: Geopolitics, Inflation, and the Fed

    William Blair macro analyst Richard de Chazal breaks down rising geopolitical tensions, sticky inflation risks, Fed policy uncertainty, and the durability of U.S. growth amid fiscal stimulus and the evolving AI-driven productivity cycle.

    Listen to the podcast

  • Meet the Portfolio Managers: Matt Fleming and Mark Goodman

    Matt Fleming and Mark Goodman share the experiences and principles that shaped their approach to value investing, the lessons that guide their decision-making, and why William Blair’s investment-led, partnership-driven culture supports long-term success for clients.

    Watch the video

  • William Blair Deepens Sector Expertise With Strategic Hires Across Chemicals, Energy, and Equity Capital Markets

    William Blair today announced another step in its continued growth with the addition of three managing directors, expanding the firm’s Industrial Growth Products team to provide enhanced coverage in the chemicals and specialty materials and in the energy transition, power, and electrification sectors, while also bolstering its comprehensive Equity Capital Markets capabilities.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures